Sep 29, 2023 | Past Events
We are delighted to invite you to our virtual briefing on 2 October 2023 to discuss the Company’s Half Year 2023 Results.Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief Financial Officer, and Dr. Emanuele Puca, Head of Investor Relations, will...Sep 29, 2023 | Past Events
Dr. Samuele Cazzamalli (Head of Chemistry) will give a talk entitled “Small Molecule Therapeutics targeting Fibroblast Activation Protein in the tumor microenvironment” (10th of October, 14.40 pm local time). Dr. Roberto De Luca will give a...Sep 29, 2023 | Past Events
Dr. Samuele Cazzamalli (Head of Chemistry) will give a virtual talk entitled “Pan-tumoral Small Molecule-Drug Conjugates Targeting Fibroblast Activation Protein in Solid Lesions” (18th of October, 14.30pm local time). Follow the link for more...Sep 29, 2023 | Past Events
Prof. Dr. Nicolas Mach, on behalf of Philogen, is presenting a poster about the Phase I DODEKA study on October 23rd, entitled “Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors” Prof. Dr. Lukas Flatz, on...Sep 29, 2023 | Past Events
Dr. Mattia Matasci is giving a presentation entitled “Philogen’s Platform for the Development of Immunocytokines”. Follow the link for more detailsSep 29, 2023 | Past Events
Dr. Roberto De Luca will give a talk entitled “Tripokin: Best-in-Class potential for tumor targeted Interleukin-2 (IL2) potentiated by Tumor Necrosis Factor (TNF)” (16th of November, 08:30 pm local time). Follow the link for more details.
Recent Comments